Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the FDA agrees to the SPA modification and the hold gets lifted, we could see a boost. If the prostate data is better than good, it may also lift the PPS. Of course nothing says "booyah" like a strong deal with upfront cash.
I assume we something after market close today or Monday AM.
I think you express the sentiments of many of us here.
There must be some members in the proximity.
Of course, it's still fairly early in the prostate trial and a small patient size but slide #15 looks very promising in the Part B portion.
I wouldn't jump the gun quite yet. I think the combo prostate data may be good but we know nothing of NEO yet. Canine data is excellent. If it equates to humans, we're in a good place.
So, please enlighten us as to the efficacy of these other treatments in development. Thanks in advance.
"In fiscal year 2018, the Company received approximately $5,000 in royalty revenue from Aratana."
Hey, it's a start.
Should be approaching the end of the extended field study then, hopefully, full approval.
Over 200K shares traded in the first 30 minutes. We don't see that every day.
I received a call.
I'm not defending KB here but I do think he at least is trying to move some things (AIM2CERV) along sooner. He stated there are term sheets, now let's get the John Hancock's and bank routing numbers.
I think even the most diehard longs realize the mistakes management has made. I've been long since the Tom Moore days and there is no denying the many missteps since then. Unlike some others, I don't fault the basic science, though.
My story is much the same as yours though I have far fewer shares. I still felt the sting. I had cautious optimisim which is now very guarded optimisim. Unlike a few, I still have faith in the science, not so much in the management.
Looking at slide #15 on the CP, it appears the combo trial is providing a definate improvement in survival. Granted, it's early and a small number in patients but, if ADXS-PSA could boost efficacy 10% in Keytruda for this indication, it could spark interest from Merck.
I beleive there is a place for Advaxis' products in the treatment of cancer and hope you, I and the rest can be made whole and eventually walk away happy.
What prelim NEO data have you seen?
One of my favorites!
phase I/II clinical trial
"A study that tests the safety, side effects, and best dose of a new treatment. Phase I/II clinical trials also test how well a certain type of cancer or other disease responds to a new treatment. In the phase II part of the clinical trial, patients usually receive the highest dose of treatment that did not cause harmful side effects in the phase I part of the clinical trial. Combining phases I and II may allow research questions to be answered more quickly or with fewer patients."
Obviously, someone did their damnedest to be sure this did not close green today!
I was still surprised they haven't partnered it yet. I thought that may be the reason for the trial delay.
They are notorious at not keeping the clinical trials page up to date. Nothing about the partial hold yet, either.
Seems as though quite a number of patents in these trials experienced a serious, life-threatening or fatal treatment-related adverse event. Based on what I've read about ADXS-PSA, the side effects seem to be less.
Wouldn't THAT be nice!
Between .03 and .05. Pretty cheap, especially if we get to $3.
If all goes well, ADXS-HER2 may get full approval soon. Management needs to step up their game for the products we still have.
This was interesting:
2019-02-12 13F CITIGROUP INC Call 400 6,400 1,500% increase
2019-02-12 13F CITIGROUP INC Put 8,600 0 -100% decrease
2019-02-12 13F CITIGROUP INC 12,506 3,906 -68.77% decrease
Hov, I have always appreciated your sane, balanced posts. I have been (probably overly) optimistic for the past several years and yet, here we sit at bargain-basement prices. Your arguments, pro and con help me to keep my expectations in-check. I will say I was puzzled (still am) as to why, with ADXS-HER2 more than doubling OS in canines and getting conditional approval, pharmas did not leap at the opportunity to get in on it. I know OS Therapies has it and I applaud their motives and intent but, really, we should have seen a better deal, IMO.
Not to rain on your parade but the company states, "suggests best-in-classCD8+T cell response". This is quite different from stating something categorically. Could there be a statement later that it IS best in class? Absolutely but, for now, it remain to be seen. I think adding the CI is very wise as I think most treatments going forward will be combos and the intermittent high volume has me wondering if, indeed, something may be in the works. Of course, I hope your thoughts come to fruition. I still want a house on Cape Cod.
Combination treatments will become the norm. Most drugs/vaccines will be used together to increase safety and efficacy. There will always be a better mouse-trap coming up from behind. Pharmas will want a treatment they can combine with their own. A company that makes a treatment that can be used with just about anything will be a winner.
I assume we'll get a PR tomorrow regarding the NEO/HOT part of the presentation. It may be enough to continue the move north.
Up over 3% AH.
Oddly, the canine vaccine may be the first fully approved Advaxis vaccine. I still think they should have spent more resources on developing a breast cancer treatment years ago.
Raja, you've hit the nail on the head. Advaxis spread themselves far too thin, considering their limited resources. I give KB credit for trying to focus on what will get to the finish line the soonest. I don't think anyone can argue with what you've stated.
If the results were so frickin good, where's the big cash deals?
Well, I guess if you discount the best ever GOG results in cervical cancer, the 8 of 9 patients who were recurrence free 42 months for anal cancer (Brown study) and the more than doubling OS of dogs with osteosarcoma, I can see your point.
Blue, what do you think of the new corp presentation?
It looks pretty good.
Not quite:
Rank Company Market Cap in 2016 (USD billions)
1 Johnson & Johnson NYSE: JNJ 314.1
2 Pfizer NYSE: PFE 196.3
3 Roche OTCQX: RHHBY 192.1
4 Novartis NYSE: NVS 170.5
5 Merck & Co. NYSE: MRK 164.3
6 Amgen NASDAQ: AMGN 108.9
7 Sanofi NYSE: SNY 101.8
8 AbbVie NYSE: ABBV 100.2
9 Bristol-Myers Squibb NASDAQ: BMY 98.2
10 Gilead Sciences NASDAQ: GILD 96.6
LOL! That made me spit out my coffee!